Phaseline

Companies › ASTEROGENE Biomedical

ASTEROGENE Biomedical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
aNPC
Autologous nucleus pulposus cells
–Phase 1Intervertebral Disc DegenerationDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07168603aNPCPhase 1Intervertebral Disc DegenerationOtherDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.